Pre-Covid-19, SARS-CoV-2-Negative Multisystem Inflammatory Syndrome in Children.
Document Type
Article
Publication Date
11-30-2023
Original Citation
Benezech S,
Khoryati L,
Cognard J,
Netea S,
Khan T,
Moreews M,
Saker K,
De Guillebon J,
Khaldi-Plassart S,
Pescarmona R,
Viel S,
Malcus C,
Perret M,
Ar Gouilh M,
Vabret A,
Venet F,
Remy S,
Chopin E,
Lina G,
Vandenesch F,
Rousseaux N,
Bastard P,
Zhang S,
Casanova J,
Trouillet-Assant S,
Walzer T,
Kuijpers T,
Javouhey E,
Dauwalder O,
Marr N,
Belot A.
Pre-Covid-19, SARS-CoV-2-Negative Multisystem Inflammatory Syndrome in Children. N Engl J Med. 2023;389(22):2105-7.
Keywords
JGM, Child, Humans, COVID-19, SARS-CoV-2, Systemic Inflammatory Response Syndrome
JAX Source
N Engl J Med. 2023;389(22):2105-7.
ISSN
1533-4406
PMID
38048195
DOI
https://doi.org/10.1056/NEJMc2307574
Abstract
To The Editor:
In early 2020, multisystemic inflammatory syndrome in children (MIS-C) was recognized as an emerging life-threatening disease occurring 2 to 6 weeks after infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with symptoms resembling those of Kawasaki’s disease or toxic shock syndrome.1 Unlike typical Kawasaki’s disease, MIS-C has been frequently associated with gastrointestinal symptoms and circulatory failure necessitating treatment with vasoactive drugs.